<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ONMEL- itraconazole tablet </strong><br>Merz Pharmaceuticals, LLC<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use ONMEL safely and effectively. See full prescribing information for ONMEL.<br><br>ONMEL (itraconazole)<br>Initial U.S. Approval: 1992</div>
<div class="Warning"><div>
<h1 class="Warning">WARNING: <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">CONGESTIVE HEART FAILURE</span>, CARDIAC EFFECTS AND DRUG INTERACTIONS</h1>
<h1 class="Warning"><span class="Italics">See full prescribing information for complete boxed warning.</span></h1>
<ul class="Disc">
<li><span class="Bold">Do not administer for the treatment of <span class="product-label-link" type="condition" conceptid="4215978" conceptname="Onychomycosis">onychomycosis</span> in patients with evidence of ventricular dysfunction such as <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> (CHF) or a history of CHF (<a href="#s4">4</a>).</span></li>
<li>If signs or symptoms of <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> occur during administration, discontinue administration. (<a href="#s4">4</a>)</li>
<li>Negative inotropic effects were seen when itraconazole was administered intravenously to dogs and healthy human volunteers. (<a href="#s5.3">5.3</a>)</li>
<li><span class="Bold">Drug Interactions: Co-administration of certain drugs is contraindicated. See complete boxed warning. (<a href="#s7">7</a>)</span></li>
<li>May increase plasma concentrations of drugs metabolized by the cytochrome P450 3A4 isoenzyme system (CYP3A4) pathway. (<a href="#s7">7</a>)</li>
<li>Serious cardiovascular events, including QT prolongation, <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsades de pointes</span>, <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span>, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>, and/or <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span> have occurred in patients using certain drugs. See complete boxed warning. (<a href="#s5.2">5.2</a>)</li>
</ul>
</div></div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning">WARNING: <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">CONGESTIVE HEART FAILURE</span>, CARDIAC EFFECTS AND DRUG INTERACTIONS</h1>
<h1 class="Warning"><span class="Italics">See full prescribing information for complete boxed warning.</span></h1>
<ul class="Disc">
<li><span class="Bold">Do not administer for the treatment of <span class="product-label-link" type="condition" conceptid="4215978" conceptname="Onychomycosis">onychomycosis</span> in patients with evidence of ventricular dysfunction such as <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> (CHF) or a history of CHF (<a href="#s4">4</a>).</span></li>
<li>If signs or symptoms of <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> occur during administration, discontinue administration. (<a href="#s4">4</a>)</li>
<li>Negative inotropic effects were seen when itraconazole was administered intravenously to dogs and healthy human volunteers. (<a href="#s5.3">5.3</a>)</li>
<li><span class="Bold">Drug Interactions: Co-administration of certain drugs is contraindicated. See complete boxed warning. (<a href="#s7">7</a>)</span></li>
<li>May increase plasma concentrations of drugs metabolized by the cytochrome P450 3A4 isoenzyme system (CYP3A4) pathway. (<a href="#s7">7</a>)</li>
<li>Serious cardiovascular events, including QT prolongation, <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsades de pointes</span>, <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span>, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>, and/or <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span> have occurred in patients using certain drugs. See complete boxed warning. (<a href="#s5.2">5.2</a>)</li>
</ul>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><ul class="Disc"><li>ONMEL, an azole antifungal, is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="4215978" conceptname="Onychomycosis">onychomycosis</span> of the toenail caused by <span class="Italics">Trichophyton rubrum</span> or <span class="Italics">T. mentagrophytes</span>. (<a href="#s1">1</a>)</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4215978" conceptname="Onychomycosis">Onychomycosis</span> of the toenail: recommended dose is 200 mg (one tablet) once daily for 12 consecutive weeks. (<a href="#s2">2</a>)</li>
<li>Take with a full meal at the same time each day. (<a href="#s2">2</a>)</li>
</ul></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul class="Disc"><li>Tablets: 200 mg (<a href="#s3">3</a>)</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disc">
<li>Do not administer for the treatment of <span class="product-label-link" type="condition" conceptid="4215978" conceptname="Onychomycosis">onychomycosis</span> in patients with evidence of ventricular dysfunction such as <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> (CHF) or a history of CHF. (<a href="#s4">4</a>)</li>
<li>Do not administer for the treatment of <span class="product-label-link" type="condition" conceptid="4215978" conceptname="Onychomycosis">onychomycosis</span> to pregnant patients or to women contemplating pregnancy. (<a href="#s4">4</a>, <a href="#s8.1">8.1</a>)</li>
<li>Co-administration of cisapride, dofetilide, ergot alkaloids such as dihydroergotamine, ergotamine, ergometrine (ergonovine), and methylergometrine (methylergonovine); felodipine, levacetylmethadol (levomethadyl), lovastatin, methadone, oral midazolam, nisoldipine, pimozide, quinidine, simvastatin, and triazolam with ONMEL is contraindicated. (<a href="#s4">4</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span> and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> have been reported with use of itraconazole. ONMEL is contraindicated in patients who have shown <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to itraconazole products. (<a href="#s4">4</a>)</li>
</ul></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>Cases of CHF, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>, and <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span> have been reported with itraconazole administration among patients being treated for <span class="product-label-link" type="condition" conceptid="4215978" conceptname="Onychomycosis">onychomycosis</span> and/or systemic <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span>. (<a href="#s5.5">5.5</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Cardiac Dysrhythmias</span>: (<a href="#s5.2">5.2</a>)</li>
<li>Cardiac Disease<span class="Italics">:</span> (<a href="#s5.3">5.3</a>)</li>
<li>Hepatic Effects: (<a href="#s5.4">5.4</a>)</li>
<li>Calcium Channel Blockers<span class="Italics">:</span> (<a href="#s5.5">5.5</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Neuropathy</span>: (<a href="#s5.6">5.6</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">Hearing Loss</span>: (<a href="#s5.7">5.7</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<ul class="Disc">
<li>Most common adverse reactions observed in the treatment phase of the <span class="product-label-link" type="condition" conceptid="4215978" conceptname="Onychomycosis">onychomycosis</span> clinical trial (&gt;1%) are <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infections</span>, increased hepatic enzymes, <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hypoacusis</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span> and <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>. (<a href="#s6.1">6.1</a>)</li>
<li>Itraconazole has been associated with rare cases of serious hepatotoxicity, including <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. (<a href="#s6.1">6.1</a>)</li>
</ul>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Merz Pharmaceuticals, LLC at 1-877-743-8454 or FDA at 1-800-FDA-1088 or <span class="Italics">www.fda.gov/medwatch.</span></span> </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul class="Disc">
<li>Concomitant administration of ONMEL Tablets with certain drugs metabolized by the cytochrome P450 3A4 isoenzyme system (CYP3A4) or transported by P-glycoprotein may result in increased plasma concentrations of those drugs, leading to potentially serious and/or life-threatening adverse events. (<a href="#s7.1">7.1</a>)</li>
<li>Drug Interactions with the following drugs or classes of drugs may occur: Antiarrhythmics, Anticonvulsants, Anti-HIV Agents, Antimycobacterials, Antineoplastics, Antipsychotics, Benzodiazepines, Calcium Channel Blockers, Gastric Acid Suppressors/Neutralizers, Gastrointestinal Motility Agents, HMG CoA-Reductase Inhibitors, Macrolide Antibiotics, Oral Hypoglycemic Agents, Polyenes, Opiate Analgesics. Not all drug interactions are included in Highlights. See Full Prescribing Information for complete listing. (<a href="#s7">7</a>)</li>
</ul></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul class="Disc">
<li>Pregnancy: Based on animal data, may cause fetal harm. (<a href="#s8.1">8.1</a>)</li>
<li>Nursing Mothers: Itraconazole is excreted in human milk. (<a href="#s8.3">8.3</a>)</li>
<li>Pediatric Use: The efficacy and safety have not been established in pediatric patients. No pharmacokinetic data are available in children. (<a href="#s8.4">8.4</a>)</li>
</ul></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 11/2012</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc"><span class="Emphasis">WARNING: <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">CONGESTIVE HEART FAILURE</span>, CARDIAC EFFECTS, AND DRUG INTERACTIONS</span></a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1	<span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span>, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Peripheral Edema</span>, and <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">Pulmonary Edema</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2	<span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Cardiac Dysrhythmias</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3	Cardiac Disease</a></h2>
<h2><a href="#section-5.4" class="toc">5.4	Hepatic Effects</a></h2>
<h2><a href="#section-5.5" class="toc">5.5	Calcium Channel Blockers</a></h2>
<h2><a href="#section-5.6" class="toc">5.6	<span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Neuropathy</span></a></h2>
<h2><a href="#section-5.7" class="toc">5.7	<span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">Hearing Loss</span></a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1	Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2	Post Marketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1	Effects of ONMEL on Other Drugs</a></h2>
<h2><a href="#section-7.2" class="toc">7.2	Effects of Other Drugs on ONMEL</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6	<span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-8.6" class="toc">8.7	<span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h2><a href="#section-11.3" class="toc">12.4 Microbiology</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-15.1" class="toc">17.1	Information for Patients</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="BOX"></a><a name="section-1"></a><p></p>
<h1><span class="Emphasis">WARNING: <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">CONGESTIVE HEART FAILURE</span>, CARDIAC EFFECTS, AND DRUG INTERACTIONS</span></h1>
<p class="First"><span class="Bold">Do not administer ONMEL for the treatment of <span class="product-label-link" type="condition" conceptid="4215978" conceptname="Onychomycosis">onychomycosis</span> in patients with evidence of ventricular dysfunction such as <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> (CHF) or a history of CHF.</span> When itraconazole was administered intravenously to dogs and healthy human volunteers, negative inotropic effects were seen. If signs or symptoms of <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> occur during administration of ONMEL, discontinue administration. <span class="Italics">[See <a href="#s4">Contraindications (4)</a>, <a href="#s5">Warnings and Precautions (5)</a>, <a href="#s7">Drug Interactions (7)</a>, and <a href="#s12">Clinical Pharmacology (12)</a>]</span></p>
<p><span class="Bold">Drug Interactions: Co-administration of cisapride, pimozide, quinidine, dofetilide, levacetylmethadol (levomethadyl), felodipine, oral midazolam, nisoldipine, triazolam, lovastatin, simvastatin, ergot alkaloids such as dihydroergotamine, ergometrine (ergonovine), ergotamine and methylergometrine (methylergonovine) or methadone with ONMEL is contraindicated.</span> ONMEL, a potent cytochrome P450 3A4 isoenzyme system (CYP3A4) inhibitor, may increase plasma concentrations of drugs metabolized by this pathway. Serious cardiovascular events, including QT prolongation, <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsades de pointes</span>, <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span>, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>, and/or <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span> have occurred in patients using cisapride, pimozide, levacetylmethadol (levomethadyl), methadone or quinidine concomitantly with itraconazole and/or other CYP3A4 inhibitors. <span class="Italics">[See <a href="#s4">Contraindications (4)</a>, <a href="#s5">Warnings and Precautions (5)</a>, and <a href="#s7">Drug Interactions (7)</a>]</span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">ONMEL is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="4215978" conceptname="Onychomycosis">onychomycosis</span> of the toenail due to <span class="Italics">Trichophyton rubrum</span> or <span class="Italics">T. mentagrophytes</span> in non-immunocompromised patients. Prior to initiating treatment, appropriate nail specimens for laboratory testing (KOH preparation, fungal culture, or nail biopsy) should be obtained to confirm the diagnosis of <span class="product-label-link" type="condition" conceptid="4215978" conceptname="Onychomycosis">onychomycosis</span>. [<span class="Italics">See <a href="#s4">Contraindications (4)</a>, <a href="#s5">Warnings and Precautions (5)</a>, <a href="#s7">Drug Interactions (7)</a>, and <a href="#s12">Clinical Pharmacology (12)</a></span>.]</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First">ONMEL should be taken with a full meal at the same time each day. The recommended dose is 200 mg (one tablet) once daily for 12 consecutive weeks.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1"></a><p></p>
<p class="First"><span class="Italics">Use in Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>:</span></p>
<p>Limited data are available on the use of oral itraconazole in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Caution should be exercised when ONMEL is administered to patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. <span class="Italics">[See <a href="#s12">Clinical Pharmacology (12)</a> and <a href="#s5">Warnings and Precautions (5)</a>.]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2"></a><p></p>
<p class="First"><span class="Italics">Use in Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>:</span></p>
<p>Limited data are available on the use of oral itraconazole in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. Caution should be exercised when ONMEL is administered to patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. <span class="Italics">[See <a href="#s12">Clinical Pharmacology (12)</a> and <a href="#s5">Warnings and Precautions (5)</a>.]</span></p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">ONMEL contain 200 mg of itraconazole, as a white to slightly grey, oblong, biconvex tablet engraved with "BARRIER" on one side and "It 200" on the other side.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.1"></a><p></p>
<p class="First"><span class="Italics"><span class="Underline"><span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span>:</span></span> Do not  administer ONMEL for the treatment of <span class="product-label-link" type="condition" conceptid="4215978" conceptname="Onychomycosis">onychomycosis</span> in patients with evidence of ventricular dysfunction such as <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> (CHF) or a history of CHF. <span class="Italics">[See <a href="#s5">Warnings and Precautions (5)</a>, <a href="#s7">Drug Interactions (7)</a>, and <a href="#s12">Clinical Pharmacology (12)</a>.]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.2"></a><p></p>
<p class="First"><span class="Italics"><span class="Underline">Drug Interactions: </span></span>Concomitant administration of ONMEL and certain drugs that are metabolized by the cytochrome P450 3A4 isoenzyme system (CYP3A4) or where gastrointestinal absorption is regulated by P-gp may result in increased plasma concentrations of those drugs, leading to potentially serious and/or life-threatening adverse events.</p>
<p>Co-administration of cisapride, dofetilide, ergot alkaloids such as dihydroergotamine, ergotamine, ergometrine (ergonovine), and methylergometrine (methylergonovine), felodipine, levacetylmethadol (levomethadyl), lovastatin, methadone, oral midazolam, nisoldipine, pimozide, quinidine, simvastatin, and triazolam with ONMEL is contraindicated.</p>
<p>Do not  administer ONMEL for the treatment of <span class="product-label-link" type="condition" conceptid="4215978" conceptname="Onychomycosis">onychomycosis</span> to pregnant patients or to women contemplating pregnancy.</p>
<p><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span> and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> have been reported with use of itraconazole. ONMEL is contraindicated for patients who have shown <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to itraconazole products.</p>
</div>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1	<span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span>, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Peripheral Edema</span>, and <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">Pulmonary Edema</span></h2>
<p class="First">Cases of CHF, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>, and <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span> have been reported with itraconazole administration among patients being treated for <span class="product-label-link" type="condition" conceptid="4215978" conceptname="Onychomycosis">onychomycosis</span> and/or systemic <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span>. [<span class="Italics">See <a href="#s4">Contraindications (4)</a>, <a href="#s5">Warnings and Precautions (5)</a>, and <a href="#s12">Clinical Pharmacology (12)</a></span>.]</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2	<span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Cardiac Dysrhythmias</span></h2>
<p class="First">Life-threatening <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac dysrhythmias</span> and/or <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span> have occurred in patients using cisapride, pimozide, levacetylmethadol (levomethadyl), methadone, or quinidine concomitantly with itraconazole and/or other CYP3A4 inhibitors. Concomitant administration of these drugs with ONMEL is contraindicated. <span class="Italics">[See <a href="#box">Boxed Warning</a>, <a href="#s4">Contraindications (4)</a>, <a href="#s5">Warnings and Precautions (5)</a>, and <a href="#s7">Drug Interactions (7)</a>.]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3	Cardiac Disease</h2>
<p class="First"><span class="Italics"><span class="Underline">ONMEL should not be administered in patients with evidence of ventricular dysfunction such as <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> (CHF) or a history of CHF.</span></span></p>
<p>Itraconazole has been shown to have a negative inotropic effect. When itraconazole was administered intravenously to anesthetized dogs, a dose-related negative inotropic effect was documented. In a healthy volunteer study of itraconazole injection, transient, asymptomatic decreases in left ventricular <span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fraction</span> were observed using gated SPECT imaging; these resolved before the next infusion, 12 hours later.</p>
<p>For patients with risk factors for <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, physicians should carefully review the risks and benefits of ONMEL therapy. These risk factors include cardiac disease such as ischemic and valvular disease; significant pulmonary disease such as <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">chronic obstructive pulmonary disease</span>; and <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> and other edematous disorders. Such patients should be informed of the signs and symptoms of CHF, should be treated with caution, and should be monitored for signs and symptoms of CHF during treatment. If signs or symptoms of CHF appear during administration of ONMEL, discontinue administration.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4	Hepatic Effects</h2>
<p class="First">Itraconazole has been associated with rare cases of serious hepatotoxicity, including <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Some of these cases had neither pre-existing liver disease nor a serious underlying medical condition, and some of these cases developed within the first week of treatment. If clinical signs or symptoms develop that are consistent with hepatotoxicity, treatment should be discontinued immediately and liver function testing performed.</p>
<p>In patients with elevated or abnormal liver enzymes or active liver disease, or who have experienced liver toxicity with other drugs, treatment with itraconazole is not recommended. Liver function monitoring should be done in patients with pre-existing hepatic function abnormalities or those who have experienced liver toxicity with other medications and should be considered in all patients receiving ONMEL.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5	Calcium Channel Blockers</h2>
<p class="First">Calcium channel blockers can have negative inotropic effects which may be additive to those of itraconazole. In addition, itraconazole can inhibit the metabolism of calcium channel blockers. Therefore, caution should be used when co-administering itraconazole and calcium channel blockers due to an increased risk of CHF. Concomitant administration of ONMEL and nisoldipine is contraindicated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5.6"></a><a name="section-5.6"></a><p></p>
<h2>5.6	<span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Neuropathy</span></h2>
<p class="First">If <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span> occurs that may be attributable to ONMEL, the treatment should be discontinued. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5.7"></a><a name="section-5.7"></a><p></p>
<h2>5.7	<span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">Hearing Loss</span></h2>
<p class="First">Transient or permanent <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hearing loss</span> has been reported in patients receiving treatment with itraconazole. Several of these reports included concurrent administration of quinidine which is contraindicated. <span class="Italics">[See <a href="#box">Boxed Warning</a>, <a href="#s5">Warnings and Precautions (5)</a>, and <a href="#s7">Drug Interactions (7)</a>.]</span> The <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hearing loss</span> usually resolves when treatment is stopped, but can persist in some patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1	Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, the adverse reaction rate observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</p>
<p>Patients in the trial for toenail <span class="product-label-link" type="condition" conceptid="4215978" conceptname="Onychomycosis">onychomycosis</span> were treated with a dosing regimen of 200 mg once daily for 12 consecutive weeks.</p>
<p>The most commonly reported adverse reaction leading to discontinuation of ONMEL was increased hepatic enzyme (6 subjects, 1.0%), followed by <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (3 subjects, 0.5%). No other adverse reaction leading to discontinuation occurred in more than one subject.</p>
<p>The table below lists all adverse reactions reported by at least 1% of patients who received ONMEL during 12 weeks of treatment:</p>
<table width="75%">
<caption><span>Table 1: Adverse Reactions Occurring at Frequencies ≥ 1% in the <span class="product-label-link" type="condition" conceptid="4215978" conceptname="Onychomycosis">Onychomycosis</span> Clinical Trial</span></caption>
<col align="left" valign="top" width="60%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<thead>
<tr class="First">
<th class="Lrule" align="left"></th>
<th class="Lrule" align="center">Incidence (%)</th>
<th class="Lrule Rrule" align="center">Incidence (%)</th>
</tr>
<tr>
<th class="Lrule" align="left">BODY SYSTEM/ADVERSE REACTION</th>
<th class="Lrule" align="center">ONMEL</th>
<th class="Lrule Rrule" align="center">Placebo tablet</th>
</tr>
<tr class="Last">
<th class="Lrule" align="left"></th>
<th class="Lrule" align="center">(N = 582)</th>
<th class="Lrule Rrule" align="center">(N = 191)</th>
</tr>
</thead>
<tbody>
<tr class="First">
<td class="Lrule Rrule" align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">INFECTIONS</span> AND <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">INFESTATIONS</span></span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper respiratory tract infections</span></td>
<td class="Rrule" align="center">6.0%</td>
<td class="Rrule" align="center">7.3%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4265485" conceptname="Bacteriuria">Bacteriuria</span></td>
<td class="Rrule" align="center">1.4%</td>
<td class="Rrule" align="center">1.6%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infection</span></td>
<td class="Rrule" align="center">1.0%</td>
<td class="Rrule" align="center">0.5%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">I<span class="Bold">NVESTIGATIONS</span>
</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  Hepatic enzymes increased</td>
<td class="Rrule" align="center">2.9%</td>
<td class="Rrule" align="center">0.0%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="320536" conceptname="Electrocardiogram abnormal">Electrocardiogram abnormal</span></td>
<td class="Rrule" align="center">1.4%</td>
<td class="Rrule" align="center">1.6%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold">EAR AND LABYRINTH DISORDERS</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">Hypoacusis</span></td>
<td class="Rrule" align="center">3.3%</td>
<td class="Rrule" align="center">3.1%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">NERVOUS SYSTEM DISORDERS</span></span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Rrule" align="center">2.2%</td>
<td class="Rrule" align="center">1.6%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Rrule" align="center">1.2%</td>
<td class="Rrule" align="center">0.0%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">GASTROINTESTINAL DISORDERS</span></span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span> or <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span></td>
<td class="Rrule" align="center">1.7%</td>
<td class="Rrule" align="center">2.6%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Rrule" align="center">1.7%</td>
<td class="Rrule" align="center">3.1%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Rrule" align="center">1.7%</td>
<td class="Rrule" align="center">1.6%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold">GENERAL DISORDERS OF ADMINISTRATION SITE CONDITIONS</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td class="Rrule" align="center">1.5%</td>
<td class="Rrule" align="center">2.6%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">CARDIAC DISORDERS</span></span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4171683" conceptname="Sinus bradycardia">Sinus Bradycardia</span></td>
<td class="Rrule" align="center">1.0%</td>
<td class="Rrule" align="center">0.0%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold">RESPIRATORY, THORACIC AND <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">MEDIASTINAL DISORDERS</span></span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></td>
<td class="Rrule" align="center">1.2%</td>
<td class="Rrule" align="center">0.0%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Pharyngolaryngeal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></td>
<td class="Rrule" align="center">1.0%</td>
<td class="Rrule" align="center">0.5%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold">MUSCULOSKELETAL AND <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">CONNECTIVE TISSUE DISORDERS</span></span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span></td>
<td class="Rrule" align="center">1.2%</td>
<td class="Rrule" align="center">2.1%</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s6.2"></a><a name="section-6.2"></a><p></p>
<h2>6.2	Post Marketing Experience</h2>
<p class="First">The following adverse reactions have been identified during post-approval use of itraconazole (all formulations) and are listed in Table 2 below. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establishing a causal relationship to drug exposure.</p>
<table width="75%">
<caption><span>Table 2: Postmarketing Reports of Adverse Reactions for Itraconazole</span></caption>
<col align="left" valign="top" width="40%">
<col align="left" valign="top" width="60%">
<tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule" align="left"><span class="Bold">Blood and lymphatic system disorders:</span></td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span></td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune system disorders</span>:</span></td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span>; anaphylactic, anaphylactoid and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>; <span class="product-label-link" type="condition" conceptid="432522" conceptname="Transfusion reaction due to serum protein reaction">serum sickness</span>; <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioneurotic edema</span></td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="Bold">Metabolism and nutritional disorders:</span></td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">Hypertriglyceridemia</span>, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span></td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span>:</span></td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Peripheral neuropathy</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoesthesia</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye disorders</span>:</span></td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">Visual disturbances</span>, including <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">vision blurred</span> and <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span></td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="Bold">Ear and labyrinth disorders:</span></td>
<td class="Rrule" align="left">Transient or permanent <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hearing loss</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span></td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac disorders</span>:</span></td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive heart failure</span></td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="Bold">Respiratory, thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">mediastinal disorders</span>:</span></td>
<td class="Rrule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">Pulmonary edema</span></td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span>:</span></td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">dysgeusia</span></td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="Bold">Hepato-biliary disorders:</span></td>
<td class="Rrule" align="left">Serious hepatotoxicity (including some cases of fatal <span class="product-label-link" type="condition" conceptid="4026032" conceptname="Acute hepatic failure">acute liver failure</span>), <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, reversible increases in hepatic enzymes</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="Bold">Skin and subcutaneous tissue disorders:</span></td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">Toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>, <span class="product-label-link" type="condition" conceptid="196431" conceptname="Hypersensitivity angiitis">leukocytoclastic vasculitis</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span></td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="Bold">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">connective tissue disorders</span>:</span></td>
<td class="Rrule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span></td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="Bold">Renal and urinary disorders:</span></td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">Urinary incontinence</span>, <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">pollakiuria</span></td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="Bold">Reproductive system and <span class="product-label-link" type="condition" conceptid="77030" conceptname="Disorder of breast">breast disorders</span>:</span></td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="196471" conceptname="Puberty bleeding">Menstrual disorders</span>, <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">erectile dysfunction</span></td>
</tr>
<tr class="Last">
<td class="Lrule" align="left"><span class="Bold">General disorders and administration site conditions:</span></td>
<td class="Rrule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Peripheral edema</span></td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="S7"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s7.1"></a><a name="section-7.1"></a><p></p>
<h2>7.1	Effects of ONMEL on Other Drugs</h2>
<p class="First">Itraconazole and its major metabolite, hydroxy-itraconazole, are strong inhibitors of the cytochrome P450 3A4 isoenzyme system (CYP3A4). Therefore, concomitant administration of ONMEL and certain drugs metabolized by the cytochrome CYP3A4 may result in increased plasma concentrations of those drugs due to decreased elimination, leading to potentially serious and/or life-threatening adverse events. Itraconazole is also an inhibitor of P-glycoprotein (P-gp) transporter and may result in increased plasma concentrations of drugs whose gastrointestinal absorption is regulated by P-gp. Whenever possible, plasma concentrations of these drugs should be monitored, and dosage adjustments made after concomitant ONMEL therapy is initiated. When appropriate, clinical monitoring for signs or symptoms of increased or prolonged pharmacologic effects is advised. Upon discontinuation, itraconazole plasma concentrations decline gradually (especially in patients with <span class="product-label-link" type="condition" conceptid="4064161" conceptname="Cirrhosis of liver">hepatic cirrhosis</span> or in those receiving CYP3A4 inhibitors). This is particularly important when initiating therapy with drugs whose metabolism is affected by itraconazole.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s7.2"></a><a name="section-7.2"></a><p></p>
<h2>7.2	Effects of Other Drugs on ONMEL</h2>
<p class="First">Inducers of CYP3A4 may decrease the plasma concentrations of itraconazole. ONMEL may not be effective in patients concomitantly taking ONMEL and one of these drugs. Therefore, administration of these drugs with ONMEL is not recommended.</p>
<p>Inhibitors of CYP3A4 may increase the plasma concentrations of itraconazole. Patients who must take ONMEL concomitantly with one of these drugs should be monitored closely for signs or symptoms of increased or prolonged pharmacologic effects of ONMEL.</p>
<a name="table3"></a><table width="75%">
<caption><span>Table 3. Selected Drugs that altered or are predicted to alter the plasma concentration of itraconazole or have their plasma concentration altered by ONMEL<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></span></caption>
<col align="left" valign="middle" width="35%">
<col align="left" valign="middle" width="65%">
<tfoot><tr><td colspan="2" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>This list is not all-inclusive.</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>For information on parenterally administered midazolam, see the <a href="#benzo">Benzodiazepine</a> paragraph below.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="Botrule First Toprule"><td class="Lrule Rrule" align="left" colspan="2"><span class="Italics">Drug plasma concentration increased by itraconazole</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Antiarrhythmics</td>
<td class="Rrule" align="left">digoxin, dofetilide, quinidine, disopyramide</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Anticonvulsants</td>
<td class="Rrule" align="left">carbamazepine</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Anti-HIV Agents</td>
<td class="Rrule" align="left">indinavir, ritonavir, saquinavir, maraviroc</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Antineoplastics</td>
<td class="Rrule" align="left">busulfan, docetaxel, vinca alkaloids</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Antipsychotics</td>
<td class="Rrule" align="left">pimozide</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Benzodiazepines</td>
<td class="Rrule" align="left">alprazolam, diazepam, midazolam,<a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a> triazolam</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Calcium Channel Blockers</td>
<td class="Rrule" align="left">dihydropyridines (including nisoldipine and felodipine), verapamil</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Gastrointestinal Motility Agents</td>
<td class="Rrule" align="left">cisapride</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">HMG CoA-Reductase Inhibitors</td>
<td class="Rrule" align="left">atorvastatin, cerivastatin, lovastatin, simvastatin</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Immunosuppressants</td>
<td class="Rrule" align="left">Cyclosporine, tacrolimus, sirolimus</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Oral Hypoglycemics</td>
<td class="Rrule" align="left">oral hypoglycemics (repaglinide)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Opiate Analgesics</td>
<td class="Rrule" align="left">fentanyl, levacetylmethadol (levomethadyl), methadone</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Polyene Antifungals</td>
<td class="Rrule" align="left">amphotericin B</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" valign="top">Other</td>
<td class="Rrule" align="left">ergot alkaloids, halofantrine, alfentanil, buspirone, methylprednisolone, budesonide, dexamethasone, fluticasone, warfarin, cilostazol, eletriptan, fexofenadine, loperamide</td>
</tr>
<tr class="Botrule">
<td align="left"> </td>
<td align="left"> </td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="2"><span class="Italics">Decrease plasma concentration of itraconazole</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Anticonvulsants</td>
<td class="Rrule" align="left">carbamazepine, phenobarbital, phenytoin</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Anti-HIV Agents</td>
<td class="Rrule" align="left">nevirapine, efavirenz</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Antimycobacterials</td>
<td class="Rrule" align="left">isoniazid, rifabutin, rifampin</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Gastric Acid Suppressors/Neutralizers</td>
<td class="Rrule" align="left" valign="bottom">antacids, H<span class="Sub">2</span>-receptor antagonists, proton pump inhibitors</td>
</tr>
<tr class="Botrule">
<td align="left"> </td>
<td align="left"> </td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="2"><span class="Italics">Increase plasma concentration of itraconazole</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Macrolide Antibiotics</td>
<td class="Rrule" align="left">clarithromycin, erythromycin</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Anti-HIV Agents</td>
<td class="Rrule" align="left">indinavir, ritonavir</td>
</tr>
</tbody>
</table>
<table width="75%">
<caption><span>Table 4. Selected Drugs that are contraindicated for use with itraconazole<a name="footnote-reference-3" href="#footnote-3" class="Sup">*</a></span></caption>
<col align="left" valign="top" width="50%">
<col align="left" valign="top" width="50%">
<tfoot><tr><td colspan="2" align="left"><dl class="Footnote">
<dt><a name="footnote-3" href="#footnote-reference-3">*</a></dt>
<dd>This list is not all-inclusive.</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">†</a></dt>
<dd>For information on parenterally administered midazolam, see the Benzodiazepine paragraph below.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Antipsychotics</td>
<td class="Rrule" align="left">pimozide</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Antiarrhythmics</td>
<td class="Rrule" align="left">dofetilide, quinidine</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Benzodiazepines</td>
<td class="Rrule" align="left">oral midazolam<a name="footnote-reference-4" href="#footnote-4" class="Sup">†</a>, triazolam</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Calcium Channel Blockers</td>
<td class="Rrule" align="left">Nisoldipine, felodipine</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Ergot Alkaloids</td>
<td class="Rrule" align="left">dihydroergotamine, ergotamine, ergometrine (ergonovine), methylergometrine (methylergonovine)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Gastrointestinal Motility Agents</td>
<td class="Rrule" align="left">cisapride</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">HMG CoA-Reductase Inhibitors</td>
<td class="Rrule" align="left">lovastatin, simvastatin</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Opiate Analgesics</td>
<td class="Rrule" align="left">levacetylmethadol (levomethadyl), methadone</td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2.1"></a><p></p>
<p class="First"><span class="Bold">Antiarrhythmics</span></p>
<p>The Class IA antiarrhythmic, quinidine and class III antiarrhythmic, dofetilide are known to prolong the QT interval. Co-administration of quinidine or dofetilide with itraconazole may increase plasma concentrations of quinidine or dofetilide, which could result in serious cardiovascular events. Therefore, concomitant administration of ONMEL and quinidine or dofetilide is contraindicated. <span class="Italics">[See <a href="#box">Boxed Warning</a>, <a href="#s4">Contraindications (4)</a>, and <a href="#s5">Warnings and Precautions (5)</a>.]</span></p>
<p>The Class IA antiarrhythmic, disopyramide has the potential to increase the QT interval at high plasma concentrations. Caution is advised when ONMEL and disopyramide are administered concomitantly.</p>
<p>Concomitant administration of digoxin and itraconazole has led to increased plasma concentrations of digoxin via inhibition of P-glycoprotein.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2.2"></a><p></p>
<p class="First"><span class="Bold">Anticonvulsants</span></p>
<p>Carbamazepine, phenobarbital, and phenytoin are all inducers of CYP3A4. Reduced plasma concentrations of itraconazole were reported when itraconazole was administered concomitantly with phenytoin. Although interactions with carbamazepine and phenobarbital have not been studied, concomitant administration of ONMEL and these drugs would be expected to result in decreased plasma concentrations of itraconazole. In addition, in vivo studies have demonstrated an increase in plasma carbamazepine concentrations in subjects concomitantly receiving ketoconazole. Although there are no data regarding the effect of itraconazole on carbamazepine metabolism, because of the similarities between ketoconazole and itraconazole, concomitant administration of ONMEL and carbamazepine may inhibit the metabolism of carbamazepine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2.3"></a><p></p>
<p class="First"><span class="Bold">Anti-HIV Agents</span></p>
<p>Non-nucleoside Reverse Transcriptase Inhibitors (NNRTI) such as nevirapine and efavirenz are inducers of CYP3A4. Human pharmacokinetic studies have shown that efavirenz, when concomitantly administered with itraconazole, greatly decreased serum concentrations of itraconazole and hydroxyl-itraconazole. Concomitant use of ONMEL and efavirenz is not recommended.</p>
<p>In vivo studies have shown that nevirapine induces the metabolism of ketoconazole, significantly reducing the bioavailability of ketoconazole. Studies involving nevirapine and itraconazole have not been conducted. However, because of the similarities between ketoconazole and itraconazole, concomitant administration of ONMEL and nevirapine is not recommended.</p>
<p>Concomitant administration of ONMEL and protease inhibitors metabolized by CYP3A4, such as indinavir, ritonavir, and saquinavir, may increase plasma concentrations of these protease inhibitors. In addition, concomitant administration of ONMEL and indinavir and ritonavir (but not saquinavir) may increase plasma concentrations of itraconazole. Caution is advised when ONMEL and protease inhibitors must be given concomitantly.</p>
<p>Concomitant administration of ONMEL and maraviroc has been reported to increase plasma concentration of maraviroc. The dose of maraviroc should be decreased to 150 mg twice daily when given in combination with itraconazole.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2.4"></a><p></p>
<p class="First"><span class="Bold">Antimycobacterials</span></p>
<p>Drug interaction studies have demonstrated that plasma concentrations of azole antifungal agents and their metabolites, including itraconazole and hydroxyitraconazole, were significantly decreased when these agents were given concomitantly with rifabutin or rifampin. In vivo data suggest that rifabutin is metabolized in part by CYP3A4. ONMEL may inhibit the metabolism of rifabutin. Although no formal study data are available for isoniazid, similar effects should be anticipated. Therefore, the efficacy of ONMEL could be substantially reduced if given concomitantly with one of these agents and co-administration is not recommended.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2.5"></a><p></p>
<p class="First"><span class="Bold">Antineoplastics</span></p>
<p>ONMEL may inhibit the metabolism of busulfan, docetaxel<span class="Bold">,</span> and vinca alkaloids.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2.6"></a><p></p>
<p class="First"><span class="Bold">Antipsychotics</span></p>
<p>Pimozide is known to prolong the QT interval and is partially metabolized by CYP3A4. Co-administration of pimozide with itraconazole could result in serious cardiovascular events. Therefore, concomitant administration of ONMEL and pimozide is contraindicated. <span class="Italics">[See <a href="#box">Boxed Warning</a>, <a href="#s4">Contraindications (4)</a>, and <a href="#s5">Warnings and Precautions (5)</a>.]</span></p>
<p>Increases in plasma aripiprazole concentrations have been demonstrated in subjects concomitantly receiving ketoconazole, requiring a reduction of the aripiprazole dose. Because of the similarities between ketoconazole and itraconazole, a similar dose reduction for aripiprazole is recommended when patients concomitantly receive itraconazole and aripiprazole.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="benzo"></a><a name="section-7.2.7"></a><p></p>
<p class="First"><span class="Bold">Benzodiazepines</span></p>
<p>Concomitant administration of itraconazole and alprazolam, diazepam, oral midazolam, or triazolam could lead to increased plasma concentrations of these benzodiazepines. Increased plasma concentrations could potentiate and prolong hypnotic and sedative effects. Concomitant administration of ONMEL and oral midazolam or triazolam is contraindicated. <span class="Italics">[See <a href="#s4">Contraindications (4)</a>, and <a href="#s5">Warnings and Precautions (5)</a>.]</span> If midazolam is administered parenterally, special precaution and patient monitoring is required since the sedative effect may be prolonged.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2.8"></a><p></p>
<p class="First"><span class="Bold">Calcium Channel Blockers</span></p>
<p>Calcium channel blockers can have a negative inotropic effect which may be additive to those of itraconazole; itraconazole can inhibit the metabolism of calcium channel blockers such as dihydropyridines (e.g., nifedipine, nisoldipine, and felodipine) and verapamil. Therefore, caution should be used when co-administering itraconazole and calcium channel blockers due to an increased risk of CHF.</p>
<p>Concomitant administration of ONMEL and nisoldipine results in clinically significant increases in nisoldipine plasma concentrations, which cannot be managed by dosage reduction, therefore the concomitant administration of ONMEL and nisoldipine is contraindicated. A clinical study showed that felodipine exposure was increased by co-administration of itraconazole, resulting in approximately 6-fold increase in the AUC and 8-fold increase in the C<span class="Sub">max</span>. The concomitant use of ONMEL and felodipine is contraindicated. <span class="Italics">[See <a href="#s4">Contraindications (4)</a>, <a href="#s5">Warnings and Precautions (5)</a>, <a href="#s7">Drug Interactions (7)</a>, and <a href="#s12">Clinical Pharmacology (12)</a>.]</span></p>
<p><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span> has been reported in patients concomitantly receiving itraconazole and dihydropyridine calcium channel blockers. Appropriate dosage adjustment may be necessary.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2.9"></a><p></p>
<p class="First"><span class="Bold">Gastric Acid Suppressors/Neutralizers</span></p>
<p>Reduced plasma concentrations of itraconazole were reported when administered concomitantly with H<span class="Sub">2</span>-receptor antagonists. Studies have shown that absorption of itraconazole is impaired when gastric acid production is decreased. ONMEL should be administered with a cola beverage if the patient has <span class="product-label-link" type="condition" conceptid="193804" conceptname="Achlorhydria">achlorhydria</span> or is taking H<span class="Sub">2</span>-receptor antagonists or other gastric acid suppressors. It is advised that antacids be administered at least 1 hour before or 2 hours after administration of ONMEL. In a clinical study, when itraconazole capsules were administered with omeprazole (a proton pump inhibitor), the bioavailability of itraconazole was significantly reduced.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2.10"></a><p></p>
<p class="First"><span class="Bold">Gastrointestinal Motility Agents</span></p>
<p>Co-administration of itraconazole with cisapride can elevate plasma cisapride concentrations, which could result in serious cardiovascular events. Therefore, concomitant administration of ONMEL with cisapride is contraindicated. <span class="Italics">[See <a href="#box">Boxed Warning</a>, <a href="#s4">Contraindications (4)</a>, and <a href="#s5">Warnings and Precautions (5)</a>.]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2.11"></a><p></p>
<p class="First"><span class="Bold">3-Hydroxy-3-Methyl-Glutaryl CoA-Reductase Inhibitors</span></p>
<p>Human pharmacokinetic data suggest that itraconazole inhibits the metabolism of atorvastatin, cerivastatin, lovastatin, and simvastatin, which may increase the risk of skeletal muscle toxicity, including <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>. Concomitant administration of ONMEL with 3-Hydroxy-3-Methyl-Glutaryl (HMG) CoA-Reductase inhibitors, such as lovastatin and simvastatin, is contraindicated. <span class="Italics">[See <a href="#s4">Contraindications (4)</a>, and <a href="#s5">Warnings and Precautions (5)</a>.]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2.12"></a><p></p>
<p class="First"><span class="Bold">Immunosuppressants</span></p>
<p>Concomitant administration of ONMEL and cyclosporine or tacrolimus has led to increased plasma concentrations of these immunosuppressants. Similarly, concomitant administration of ONMEL  and sirolimus could increase plasma concentrations of sirolimus.</p>
<p>Monitoring of blood concentrations of cyclosporine, tacrolimus, or sirolimus are recommended when ONMEL are co-administered with these immunosuppressants and appropriate dosage adjustments should be made.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2.13"></a><p></p>
<p class="First"><span class="Bold">Macrolide Antibiotics</span></p>
<p>Erythromycin and clarithromycin are known inhibitors of CYP3A4 (See <a href="#table3">Table 3</a>) and may increase plasma concentrations of itraconazole.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2.14"></a><p></p>
<p class="First"><span class="Bold">Oral Hypoglycemic Agents</span></p>
<p>Severe <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> has been reported in patients concomitantly receiving azole antifungal agents and oral hypoglycemic agents. A human pharmacokinetic study showed that co-administration with itraconazole and a single dose of repaglinide (on the third day of a regimen of 200 mg initial dose, twice-daily 100 mg itraconazole) resulted in a 1.4-fold higher repaglinide AUC. Blood glucose concentrations should be carefully monitored when ONMEL and oral hypoglycemic agents are co-administered.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2.15"></a><p></p>
<p class="First"><span class="Bold">Polyenes Antifungal Agents</span></p>
<p>Prior treatment with itraconazole, like other azoles, may reduce or inhibit the activity of polyenes such as amphotericin B. However, the clinical significance of this drug effect has not been clearly defined.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2.16"></a><p></p>
<p class="First"><span class="Bold">Opiate Analgesics</span></p>
<p>Levacetylmethadol (levomethadyl) and methadone are known to prolong the QT interval and are metabolized by CYP3A4. Co-administration of methadone or levacetylmethadol with itraconazole could result in serious cardiovascular events. Therefore, concomitant administration of ONMEL and methadone or levacetylmethadol are contraindicated.</p>
<p>Fentanyl plasma concentrations could be increased or prolonged by concomitant use of itraconazole and may cause potentially fatal <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>.</p>
<p>In vitro data suggest that alfentanil is metabolized by CYP3A4. Administration with itraconazole may increase plasma concentrations of alfentanil.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2.17"></a><p></p>
<p class="First"><span class="Bold">Other</span></p>
<ul class="Disc">
<li>Elevated concentrations of ergot alkaloids can cause <span class="product-label-link" type="condition" conceptid="4201303" conceptname="Ergotism">ergotism</span>, i.e., a risk for <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span> potentially leading to <span class="product-label-link" type="condition" conceptid="374384" conceptname="Cerebral ischemia">cerebral ischemia</span> and/or <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span> of the extremities. Concomitant administration of ergot alkaloids such as dihydroergotamine, ergometrine (ergonovine), ergotamine and methylergometrine (methylergonovine) with ONMEL is contraindicated.</li>
<li>Halofantrine has the potential to prolong the QT interval at high plasma concentrations. Caution is advised when ONMEL and halofantrine are administered concomitantly.</li>
<li>Human pharmacokinetic data suggest that concomitant administration of itraconazole and buspirone results in significant increases in plasma concentrations of buspirone.</li>
<li>Itraconazole may inhibit the metabolism of certain glucocorticosteroids such as budesonide, dexamethasone, fluticasone and methylprednisolone.</li>
<li>Itraconazole enhances the anticoagulant effect of coumarin-like drugs, such as warfarin.</li>
<li>Cilostazol and eletriptan are CYP3A4 metabolized drugs that should be used with caution when co-administered with ONMEL.</li>
<li>Co-administration of itraconazole with meloxicam decreased peak plasma concentrations and the exposure of meloxicam by 64% and 37%, respectively. Monitor patients for responses to meloxicam when itraconazole is concomitantly administered and dose adjustment should be considered if warranted.</li>
<li>Co-administration of itraconazole with fexofenadine increased the peak plasma concentration and the total exposure of fexofenadine by approximately 3-fold and augmented its anti-histamine effects.</li>
<li>Co-administration of itraconazole with loperamide increased peak plasma concentrations of loperamide by 3-fold and the total exposure by 3.9-fold. In addition, itraconazole is an inhibitor of P-glycoprotein and may inhibit the transport of loperamide out of the brain, leading to elevated concentrations of loperamide in the brain. Patients should be monitored for signs and symptoms of loperamide <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, such as <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span>, including <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> and <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, and a dose or dosing frequency should be adjusted as necessary.</li>
</ul>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="S8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-8.1.1"></a><p></p>
<p class="First"><span class="Bold">Teratogenic effects. Pregnancy Category C </span></p>
<p>There are no adequate and well-controlled clinical trials in the pregnant women with itraconazole. However, cases of congenital abnormalities have been reported with itraconazole drug products in post-marketing reports. Therefore, ONMEL should not be administered to pregnant women, women planning pregnancy, or women of child bearing potential unless these <span class="product-label-link" type="condition" conceptid="4215978" conceptname="Onychomycosis">onychomycosis</span> patients are using effective contraception measures to prevent pregnancy. Effective contraceptive measures should continue throughout the treatment period and for two months thereafter. ONMEL should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
<p>Itraconazole produced a significant dose-related increase in maternal toxicity, embryotoxicity, and <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> in rats at dose levels of 40-160 mg/kg/day (2-10 times the maximum recommended human dose [MRHD], based on mg/m<span class="Sup">2</span>/day comparisons), and in mice at 80 mg/kg/day (2 times MRHD, based on mg/m<span class="Sup">2</span>/day comparisons). Teratogenic changes in rats included major skeletal defects; <span class="product-label-link" type="condition" conceptid="432419" conceptname="Encephalocele">encephalocele</span> and/or macroglossia developed in mice.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="S8.3"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Itraconazole is excreted in human milk; therefore, the expected benefits of ONMEL therapy for the mother should be weighed against the potential risk from exposure of itraconazole to the infant.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="S8.4"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">The safety and effectiveness of ONMEL in pediatric patients have not been established. No pharmacokinetic data on ONMEL are available in children.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="S8.5"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">ONMEL was evaluated in 42 of 593 subjects (7.1%) greater than 65 years of age.</p>
<p>Transient or permanent <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hearing loss</span> has been reported in elderly patients receiving treatment with itraconazole. Several of these reports included concurrent administration of quinidine which is contraindicated. <span class="Italics">[See <a href="#box">Boxed Warning</a>, <a href="#s4">Contraindications (4)</a>, <a href="#s7">Drug Interactions (7)</a>, and <a href="#s5">Warnings and Precautions (5)</a>.] </span>Itraconazole should be used with care in elderly patients. <span class="Italics">[See <a href="#s5">Warnings and Precautions (5)</a>.]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s8.6"></a><a name="section-8.5"></a><p></p>
<h2>8.6	<span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Limited data are available on the use of oral itraconazole in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Caution should be exercised when ONMEL is administered to patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. <span class="Italics">[See Clinical Pharmacology (12.5) and <a href="#s2">Dosage and Administration (2)</a>.]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s8.7"></a><a name="section-8.6"></a><p></p>
<h2>8.7	<span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">Limited data are available on the use of oral itraconazole in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. Caution should be exercised when ONMEL is administered to patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. <span class="Italics">[See Clinical Pharmacology (12.5) and <a href="#s2">Dosage and Administration (2)</a>.]</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="S10"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">Itraconazole is not removed by dialysis. In the event of accidental overdosage, supportive measures, including gastric lavage with sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span>, should be employed.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="S11"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">ONMEL (itraconazole) is a synthetic triazole antifungal agent for oral use. Itraconazole is a 1:1:1:1 racemic mixture of four diastereomers (two enantiomeric pairs), each possessing three chiral centers. It may be represented by the following structural formula and nomenclature:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=fb8a2e5b-fd23-4977-81de-a95f4af168e2&amp;name=onmel-01.jpg"></div>
<p>(±)-<span class="Underline">cis</span>-4-[4-[4-[4[[2-(2,4-dichlorophenyl)-2-(1<span class="Underline">H</span>-1,2,4-triazol-1-ylmethyl)-1,3-dioxolane-4-yl]methoxy]phenyl]-1-piperazinyl]phenyl]-2,4-dihydro-2-(1-methylpropyl)-3<span class="Underline">H</span>-1,2,4-triazol-3-one</p>
<p>Itraconazole has a molecular formula of C<span class="Sub">35</span>H<span class="Sub">38</span>Cl<span class="Sub">2</span>N<span class="Sub">8</span>O<span class="Sub">4</span> and a molecular weight of 705.64. It is a white to slightly yellowish powder. It is insoluble in water, very slightly soluble in alcohols, and freely soluble in dichloromethane. It has a pKa of 3.70 (based on extrapolation of values obtained from methanolic solutions) and a log (n-octanol/water) partition coefficient of 5.66 at pH 8.1.</p>
<p>Each ONMEL is formulated for melt extrusion technology and contains 200 mg of itraconazole and the following inactive ingredients: colloidal silicon dioxide, crospovidone, hydrogenated vegetable oil, hypromellose, lactose, microcrystalline cellulose, magnesium stearate, propylene glycol, talc, and titanium dioxide.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="S12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Itraconazole, an azole, is an antifungal agent [<span class="Italics">See <a href="#s12">Clinical Pharmacology (12)</a> and <a href="#s12.4">Microbiology (12.4)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="S12.3"></a><a name="section-11.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">The oral bioavailability of itraconazole is increased when ONMEL is taken with a FDA standard high-fat meal. The pharmacokinetic parameters of itraconazole and hydroxy-itraconazole after administration of one ONMEL to 9 male and 9 female healthy subjects in fasting and in fed conditions are presented in the table below:</p>
<table width="75%">
<caption><span>Table 5: Pharmacokinetic Parameters Following a Single Dose of ONMEL (mean ± SD)<a name="footnote-reference-5" href="#footnote-5" class="Sup">*</a></span></caption>
<col align="left" valign="middle" width="24%">
<col align="left" valign="middle" width="19%">
<col align="left" valign="middle" width="19%">
<col align="left" valign="middle" width="19%">
<col align="left" valign="middle" width="19%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="center" rowspan="2"></th>
<th class="Rrule" align="center" colspan="2">Itraconazole</th>
<th class="Rrule" align="center" colspan="2">Hydroxy-itraconazole</th>
</tr>
<tr class="Last">
<th class="Rule" align="center">Fed</th>
<th class="Rrule" align="center">Fasted</th>
<th class="Rrule" align="center">Fed</th>
<th class="Rrule" align="center">Fasted</th>
</tr>
</thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-5" href="#footnote-reference-5">*</a></dt>
<dd><span class="Underline">Drug given after FDA standard high-fat breakfast</span></dd>
<dt><a name="footnote-6" href="#footnote-reference-6">†</a></dt>
<dd>mean ± standard deviation</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">C<span class="Sub">max</span> (ng/mL)</td>
<td class="Rrule" align="left">213 ± 117<a name="footnote-reference-6" href="#footnote-6" class="Sup">†</a>
</td>
<td class="Rrule" align="left">162 ± 107</td>
<td class="Rrule" align="left">332 ± 118</td>
<td class="Rrule" align="left">264 ± 109</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">T<span class="Sub">max</span> (hours)</td>
<td class="Rrule" align="left">4.6 ± 2.2</td>
<td class="Rrule" align="left">2.9 ± 0.8</td>
<td class="Rrule" align="left">5.7 ± 2.6</td>
<td class="Rrule" align="left">3.4 ± 0.8</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">AUC<span class="Sub">0</span><span class="Sub">-∞</span> (μg.h/mL)</td>
<td class="Rrule" align="left">3.34 ± 1.98</td>
<td class="Rrule" align="left">2.27 ± 1.44</td>
<td class="Rrule" align="left">7.05 ± 3.94</td>
<td class="Rrule" align="left">4.58 ± 2.80</td>
</tr>
</tbody>
</table>
<p>The steady-state pharmacokinetics of itraconazole and hydroxy-itraconazole were analyzed after oral dosing of 16 healthy volunteers with one ONMEL <span class="Underline">following a moderate-fat breakfast</span> once daily for 14 days in an open-label study. Mean maximum plasma levels of itraconazole and hydroxy-itraconazole increased from Day 1 to Day 14 by approximately 6- and 4-fold, respectively. The respective pharmacokinetic parameters from this study are reflected in the table below:</p>
<table width="75%">
<caption><span>Table 6: Pharmacokinetic Parameters Following Multiple Doses of ONMEL (mean ± SD) Taken with Moderate-fat Breakfasts<a name="footnote-reference-7" href="#footnote-7" class="Sup">*</a></span></caption>
<col align="left" valign="middle" width="20%">
<col align="left" valign="middle" width="20%">
<col align="center" valign="middle" width="10%">
<col align="center" valign="middle" width="25%">
<col align="center" valign="middle" width="25%">
<thead><tr class="First Last">
<th align="left"></th>
<th align="left" valign="bottom">Statistic</th>
<th align="center" valign="bottom">Day</th>
<th align="center" valign="bottom">Itraconazole<br>N=16</th>
<th align="center" valign="bottom">Hydroxy-itraconazole<br>N=16</th>
</tr></thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-7" href="#footnote-reference-7">*</a></dt>
<dd>Meal containing approximately 500 calories, 30% of which were derived from fat.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule" align="left" rowspan="2">
<span class="Bold">C<span class="Sub">max</span></span> (ng/mL)</td>
<td class="Botrule" align="left" rowspan="2">Mean (SD)</td>
<td align="center">1</td>
<td align="center">116.8 (43.34)</td>
<td align="center">221.7 (69.21)</td>
</tr>
<tr class="Botrule">
<td align="center">14</td>
<td align="center">658.1 (362.16)</td>
<td align="center">974.2 (479.92)</td>
</tr>
<tr>
<td class="Botrule" align="left" rowspan="2">
<span class="Bold">AUC<span class="Sub">0-24</span></span> (ng*h/mL)</td>
<td class="Botrule" align="left" rowspan="2">Mean (SD)</td>
<td align="center">1</td>
<td align="center">905.09 (384.239)</td>
<td align="center">2538.33 (1057.872)</td>
</tr>
<tr class="Botrule">
<td align="center">14</td>
<td align="center">9046.81 (5320.516)</td>
<td align="center">19054.95 (10443.214)</td>
</tr>
<tr>
<td class="Botrule" align="left" rowspan="2">
<span class="Bold">T<span class="Sub">max</span></span> (h)</td>
<td class="Botrule" align="left" rowspan="2">Median<br>(Min-Max)</td>
<td align="center">1</td>
<td align="center">4.00 (2.00-5.00)</td>
<td align="center">4.00 (2.00-5.00)</td>
</tr>
<tr class="Botrule">
<td align="center">14</td>
<td align="center">4.00 (1.00-24.00)</td>
<td align="center">4.00 (3.00-24.00)</td>
</tr>
<tr class="Last">
<td align="left">
<span class="Bold">T<span class="Sub">1/2</span></span> (h)</td>
<td align="left">Mean (SD)</td>
<td align="center">14</td>
<td align="center">36.84 (10.378)</td>
<td align="center">20.06 (6.998)</td>
</tr>
</tbody>
</table>
<p>In a 2-period, open-label, randomized, cross-over, pivotal bioequivalence study to assess the comparative bioavailability of the ONMEL and a marketed 100-mg itraconazole capsule, 28 male and 28 female healthy subjects were given as a single dose, 200 mg of itraconazole immediately after a moderate-fat breakfast (<span class="Underline">same caloric and fat contents as in the table above</span>). Fifty-two subjects were included in the final analysis.</p>
<p>The C<span class="Sub">max</span> of the ONMEL was comparable to that of the 2 itraconazole 100-mg capsules while AUC<span class="Sub">t</span> and AUC<span class="Sub">∞</span> were about 15% higher with the ONMEL.</p>
<p>In another 2-period, open-label, randomized, cross-over, pivotal bioequivalence study, 28 male and 28 female healthy subjects were given one ONMEL or two 100-mg itraconazole capsules following the FDA standard high-fat breakfast. The C<span class="Sub">max</span> and AUC<span class="Sub">∞</span> of the ONMEL were 20 and 30% lower, respectively, than those of two itraconazole 100-mg capsules. Overall, the inter-subject variability was high and coefficient of variances (CV) for AUCs in the above two studies were 44-66%.</p>
<p>Itraconazole is metabolized predominately by the cytochrome P450 3A4 isoenzyme system (CYP3A4), resulting in the formation of several metabolites. Hydroxyitraconazole, the major metabolite, has <span class="Italics">in vitro</span> antifungal activity comparable to itraconazole. Results of a pharmacokinetics study suggest that itraconazole may undergo saturable metabolism with multiple dosing. Based on an oral dose, fecal excretion of the parent drug varies between 3-18% of the dose. Itraconazole is excreted mainly as inactive metabolites in the urine (35%) and feces (54%) within one week of an oral dose. No single excreted metabolite represents more than 5% of a dose. The plasma protein binding of itraconazole has been reported to be 99.8% and that of hydroxy-itraconazole is 99.5%. <span class="Italics">[See <a href="#s4">Contraindications (4)</a>.]</span></p>
</div>
<div class="Section" data-sectionCode="49489-8">
<a name="s12.4"></a><a name="section-11.3"></a><p></p>
<h2>12.4 Microbiology</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.1"></a><p></p>
<p class="First"><span class="Italics"><span class="Underline">Mechanism of Action</span></span></p>
<p>Itraconazole inhibits the cytochrome P450-dependent synthesis of ergosterol, which is a vital component of fungal cell membranes.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.2"></a><p></p>
<p class="First"><span class="Italics"><span class="Underline">Activity In Vitro</span></span></p>
<p>Itraconazole exhibits <span class="Italics">in vitro </span>activity against <span class="Italics">Trichophyton </span><span class="Italics">rubrum</span> and <span class="Italics">Trichophyton mentagrophytes</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.3"></a><p></p>
<p class="First"><span class="Italics"><span class="Underline">Resistance</span></span></p>
<p>Isolates from several fungal species with decreased susceptibility to itraconazole have been isolated from patients receiving prolonged therapy.</p>
<p>Several <span class="Italics">in vitro</span> studies have reported that some fungal clinical isolates with reduced susceptibility to one azole antifungal agent may also be less susceptible to other azole derivatives. The finding of cross-resistance is dependent on a number of factors, including the species evaluated, its clinical history, the particular azole compounds compared, and the type of susceptibility test that is performed. The relevance of these <span class="Italics">in vitro</span> susceptibility data to clinical outcome remains to be elucidated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.4"></a><p></p>
<p class="First"><span class="Bold">Special Populations</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.4.1"></a><p></p>
<p class="First"><span class="Italics Underline"><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span></span></p>
<p>Limited data are available on the use of oral itraconazole in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. A pharmacokinetic study using a single 200-mg dose of itraconazole was conducted in three groups of patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (<span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">uremia</span>: n=7; hemodialysis: n=7; and continuous ambulatory peritoneal dialysis: n=5). In uremic subjects with a mean creatinine clearance of 13 mL/min. × 1.73 m<span class="Sup">2</span>, the exposure, based on AUC, was slightly reduced compared with normal population parameters. The study did not demonstrate any significant effect of hemodialysis or continuous ambulatory peritoneal dialysis on the pharmacokinetics of itraconazole (T<span class="Sub">max</span>, C<span class="Sub">max</span>, and AUC<span class="Sub">0-8</span>). Plasma concentration-versus-time profiles showed wide intersubject variation in all three groups. Caution should be exercised when the drug is administered in this population. <span class="Italics">[See <a href="#s5">Warnings and Precautions (5)</a> and <a href="#s2">Dosage and Administration (2)</a>.]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.4.2"></a><p></p>
<p class="First"><span class="Italics Underline"><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span></span></p>
<p>Itraconazole is predominantly metabolized in the liver. Patients with impaired hepatic function should be carefully monitored when taking itraconazole. A pharmacokinetic study using a single oral 100 mg dose of itraconazole was conducted in 6 healthy and 12 cirrhotic subjects. A statistically significant reduction in mean C<span class="Sub">max</span> (47%) and a twofold increase in the elimination half-life (37 ± 17 hours vs. 16 ± 5 hours) of itraconazole were noted in cirrhotic subjects compared with healthy subjects. However, overall exposure to itraconazole, based on AUC, was similar in cirrhotic patients and in healthy subjects. The prolonged elimination half-life of itraconazole observed in the single oral dose clinical trial with itraconazole in cirrhotic patients should be considered when deciding to initiate therapy with other medications metabolized by CYP3A4. Data are not available in cirrhotic patients during long-term use of itraconazole. <span class="Italics">[See <a href="#box">Boxed Warning</a>, <a href="#s4">Contraindications (4)</a>, <a href="#s5">Warnings and Precautions (5)</a>, and <a href="#s2">Dosage and Administration (2)</a>.]</span></p>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="S13"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="S13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">No carcinogenicity, mutagenicity, or impairment of fertility studies were conducted with ONMEL.</p>
<p>Itraconazole did not exhibit any carcinogenic potential in mice receiving oral doses up to 80 mg/kg/day (2 times MRHD, based on mg/m<span class="Sup">2</span>/day comparisons) for 23 months. A slightly increased incidence of soft tissue <span class="product-label-link" type="condition" conceptid="4084784" conceptname="Sarcoma">sarcoma</span> was observed in male rats administered 25 mg/kg/day (1.3 times MRHD, based on mg/m<span class="Sup">2</span>/day comparisons). These tumors may have been related to <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span> caused by chronic treatment with itraconazole in rats; <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span> is not observed with such treatment in dogs or humans. Compared to untreated controls, female rats receiving 50 mg/kg/day (2.5 times MRHD, based on mg/m<span class="Sup">2</span>/day comparisons) had a statistically insignificant increase in squamous cell carcinoma in lungs (2/50), an uncommon tumor in rats.</p>
<p>Itraconazole did not exhibit any mutagenic or genotoxic effects when evaluated in a DNA repair test (unscheduled DNA synthesis) in primary rat hepatocytes, in Ames tests (6 <span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span></span> <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> and <span class="Italics">E. coli</span>), in the mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> gene mutation test, in a sex-linked recessive lethal mutation (<span class="Italics">Drosophila melanogaster</span>) test, in chromosome aberration test (human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>), in a cell transformation assay (C3H/10T<span class="Sup">½</span> C18 mouse embryo fibroblasts), in a dominant lethal mutation test in male and female mice, and in micronucleus tests in mice and rats.</p>
<p>Itraconazole did not affect the fertility in male or female rats treated with oral doses up to 40 mg/kg/day (2 times MRHD, based on mg/m<span class="Sup">2</span>/day comparisons); however, parental toxicity occurred at this dosage. More severe parental toxicity was observed at 160 mg/kg/day (10 times MRHD, based on mg/m<span class="Sup">2</span>/day comparisons).</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="S14"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">The efficacy of ONMEL for the treatment of <span class="product-label-link" type="condition" conceptid="4215978" conceptname="Onychomycosis">onychomycosis</span> of the toenail was examined in a randomized, multi-center, placebo-controlled, third-party blinded trial comparing ONMEL to two 100 mg itraconazole capsules and placebo tablets.</p>
<p>In the clinical study, 791 subjects with diagnosis of distal and/or lateral subungual <span class="product-label-link" type="condition" conceptid="4215978" conceptname="Onychomycosis">onychomycosis</span> were randomized to ONMEL (N= 593) or placebo tablets (N= 198) once daily for 12 consecutive weeks. The median age of subjects enrolled in the trial was 48 years and 75% were males. At baseline, 95.1% of subjects had <span class="product-label-link" type="condition" conceptid="4215978" conceptname="Onychomycosis">onychomycosis</span> due to <span class="Italics">T. rubrum</span> with a baseline global severity score of 'Moderate' which was defined as a target toenail involvement ≤50% dystrophy and/or discoloration with clear evidence of subungual <span class="product-label-link" type="condition" conceptid="4098436" conceptname="Hyperkeratosis">hyperkeratosis</span> and/or <span class="product-label-link" type="condition" conceptid="4328079" conceptname="Onycholysis">onycholysis</span>.</p>
<p>The primary endpoint was the proportion of subjects with a Complete Cure at Week 52, nine months after completion of study medication. A Complete Cure was defined as both a Clinical Cure (no evidence of <span class="product-label-link" type="condition" conceptid="4215978" conceptname="Onychomycosis">onychomycosis</span> in target nail; normal nail unit without subungual <span class="product-label-link" type="condition" conceptid="4098436" conceptname="Hyperkeratosis">hyperkeratosis</span> or <span class="product-label-link" type="condition" conceptid="4328079" conceptname="Onycholysis">onycholysis</span>) and Mycological Cure (negative KOH and negative culture). The following table illustrates the study results for ONMEL and Placebo:</p>
<table width="75%">
<caption><span>Table 7: Primary Efficacy Results at Week 52</span></caption>
<col align="left" valign="top" width="34%">
<col align="left" valign="top" width="33%">
<col align="left" valign="top" width="33%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left">Endpoint</th>
<th class="Rrule" align="left">ONMEL<br>N=593</th>
<th class="Rrule" align="left">Placebo<br>N=198</th>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-8" href="#footnote-reference-8">*</a></dt>
<dd>Complete Cure defined as Clinical Cure (no evidence of <span class="product-label-link" type="condition" conceptid="4215978" conceptname="Onychomycosis">onychomycosis</span> in target nail; normal nail unit without subungual <span class="product-label-link" type="condition" conceptid="4098436" conceptname="Hyperkeratosis">hyperkeratosis</span> or <span class="product-label-link" type="condition" conceptid="4328079" conceptname="Onycholysis">onycholysis</span>) and Mycological Cure (negative KOH and negative culture)</dd>
</dl></td></tr></tfoot>
<tbody><tr class="First Last">
<td class="Lrule Rrule" align="left">Complete Cure<a name="footnote-reference-8" href="#footnote-8" class="Sup">*</a>
</td>
<td class="Rrule" align="left">22.3%</td>
<td class="Rrule" align="left">1.0%</td>
</tr></tbody>
</table>
<p>The Mycologic Cure rate was 44% and the Clinical Cure rate was 26% for subjects treated with ONMEL. Comparatively, the Mycological Cure rate was 6% and the Clinical Cure rate was 3% for subjects treated with Placebo Tablets.</p>
<p>Efficacy results comparing ONMEL to 200 mg of itraconazole capsules (two 100 mg capsules) were similar.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="S16"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<div class="Section" data-sectionCode="34069-5">
<a name="section-14.1"></a><p></p>
<p class="First"><span class="Bold">How Supplied</span></p>
<p>ONMEL is available containing 200 mg of itraconazole, as a white to slightly grey, oblong, biconvex tablet engraved with "BARRIER" on one side and "It 200" on the other side. Each carton (NDC 0259-1420-28) contains two <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> cards of 14 tablets each (NDC 0259-1420-14).</p>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="section-14.2"></a><p></p>
<p class="First"><span class="Bold">Storage</span></p>
<p>Store at controlled room temperature 15° to 25°C (59° to 77°F). Excursions permitted to 15° to 30°C (59° to 86°F). Protect from light and moisture. Keep out of reach of children.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="S17"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First"><span class="Italics">[See <a href="#fda">FDA-approved Patient Labeling</a>.]</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="s17.1"></a><a name="section-15.1"></a><p></p>
<h2>17.1	Information for Patients</h2>
<ul class="Disc"><li>Instruct patients that <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hearing loss</span> can occur with the use of itraconazole. The <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hearing loss</span> usually resolves when treatment is stopped, but can persist in some patients. Advise patients to inform their physicians if any <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hearing loss</span> occurs.</li></ul>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16"></a><p></p>
<p class="First">ONM:3PI</p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="fda"></a><a name="section-17"></a><p></p>
<p class="First"><span class="Bold">FDA-Approved Patient Labeling</span></p>
<p>ONMEL (itraconazole)</p>
<p>Read this Patient Information before you start using ONMEL and each time you get a refill. There may be new information. This information does not take the place of talking with your doctor about your medical condition or treatment.</p>
<p><a name="important"></a><span class="Bold">What is the most important information I should know about ONMEL?</span></p>
<p><span class="Bold">ONMEL can cause serious life-threatening side effects, including:</span></p>
<dl class="Disc">
<dt class="Bold">1.</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span></span>. <span class="Bold">Do not take ONMEL if you have had <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, including <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>.</span><p class="First"><span class="Bold">Stop taking ONMEL and call your doctor right away if you have any of these symptoms of <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>:</span></p>
<table class="Noautorules" width="75%">
<col align="left" valign="top" width="50%">
<col align="left" valign="top" width="50%">
<tbody class="Headless"><tr>
<td align="left"><ul class="Square">
<li><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span></li>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your feet, ankles, or legs</li>
<li>sudden <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span></li>
<li>increased <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span></li>
</ul></td>
<td align="left"><ul class="Square">
<li><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span> up white or pink <span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">phlegm</span></li>
<li>fast heartbeat</li>
<li>waking up at night more than normal for you</li>
</ul></td>
</tr></tbody>
</table>
</dd>
<dt class="Bold">2.</dt>
<dd>
<span class="Bold">Serious cardiovascular effects. Do not take ONMEL if you also take the following medicines:</span><table class="Noautorules" width="75%">
<col align="left" valign="top" width="50%">
<col align="left" valign="top" width="50%">
<tbody class="Headless"><tr>
<td align="left"><ul class="Square">
<li>cisapride (Propulsid)</li>
<li>pimozide (Orap)</li>
<li>quinidine (Quindine Gluconate, Quindine</li>
<li>Sulfate)</li>
<li>dofetilide (Tikosyn)</li>
<li>levomethadyl (Oralaam)</li>
<li>midazolam (Versed)</li>
<li>felodipine, nisoldipine (Lexxel, Plendil, Sular)</li>
</ul></td>
<td align="left"><ul class="Square">
<li>triazolam (Halcion)</li>
<li>lovastatin (Mevacor, Advicor, Altoprev)</li>
<li>simvastatin (Zocor, Simcor, Vytorin)</li>
<li>ergot alkaloids (Migranal, Ergonovine, Cafergot, Methergine, Dihydroergotamine Mesylate, Methylergonovine)</li>
<li>methadone (Dolophine)</li>
</ul></td>
</tr></tbody>
</table>
<p class="First">This is not a complete list of medicines that can interact with ONMEL.</p>
</dd>
<dt>•</dt>
<dd>Before taking ONMEL, tell your doctor about all the medicine you take, including prescription and non-prescription medicines, vitamins, and herbal supplements.</dd>
<dt>•</dt>
<dd>Before you start any new medicine, ask your doctor or pharmacist if it is safe to take it with ONMEL.</dd>
</dl>
<p><span class="Bold">What is ONMEL?</span></p>
<p>ONMEL is a prescription medicine used to treat <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span> of the toenails. It is not known if ONMEL is safe and effective in children under the age of 18.</p>
<p><a name="Who"></a><span class="Bold">Who should not take ONMEL?</span></p>
<p><span class="Bold">Do not</span> take ONMEL if you:</p>
<ul class="Disc">
<li>have or had <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, including <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>.</li>
<li>Take certain medicines. See "<a href="#important">What is the most important information I should know about ONMEL?</a>"</li>
<li>are pregnant or plan to become pregnant. ONMEL can harm your unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant.</li>
<li>have ever had an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to itraconazole or any of the other ingredients in ONMEL. Ask your doctor or pharmacist for a list of these ingredients.</li>
</ul>
<p><span class="Bold">What should I tell my doctor before taking ONMEL?</span></p>
<p>Before taking ONMEL, tell your doctor if you:</p>
<ul class="Disc">
<li>have or had heart, lung, liver or kidney problems</li>
<li>have any other medical conditions</li>
<li>
<span class="Bold">are pregnant or planning to become pregnant</span>. See "<a href="#Who">Who should not take ONMEL?</a>". Females who can become pregnant should use effective birth control during treatment with ONMEL and for 2 months after you stop treatment with ONMEL. Talk to your doctor about the type of birth control that is best for you while taking ONMEL.</li>
<li>are breast-feeding or plan to breast-feed. ONMEL can pass into your breastmilk and may harm your baby. Talk to your doctor about the best way to feed your baby if you take ONMEL.</li>
</ul>
<p><span class="Bold">Tell your doctor about all the medicines you take, </span>including prescription and non-prescription medicines, vitamins, and herbal supplements.</p>
<p>Taking ONMEL with certain other medicines could lead to serious or life-threatening medical problems.</p>
<ul class="Disc">
<li>See <span class="Bold">"<a href="#important">What is the most important information I should know about ONMEL?</a>"</span>
</li>
<li><span class="Bold">Fentanyl. Taking fentanyl, a strong opioid narcotic main medicine with ONMEL could cause serious breathing problems that can lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</span></li>
</ul>
<p>Talk to your doctor or pharmacist before you start any new medicine. They can tell you if it is safe to take ONMEL with your other medicines.</p>
<p>Know the medicines you take. Keep a list of your medicines and show it to your doctor and pharmacist when you get a new medicine.</p>
<p><span class="Bold">How should I take ONMEL?</span></p>
<p>Take ONMEL exactly as prescribed by your doctor. Be sure to finish all of your ONMEL as prescribed by your doctor.</p>
<ul class="Disc">
<li>ONMEL comes in a 14 tablet blisterpack container.</li>
<li>Take ONMEL with a full meal at the same time each day.</li>
<li>Your doctor should do blood tests to check your liver function before you start and while you take ONMEL, especially if you have liver problems.</li>
<li>If you forget to take or miss doses of ONMEL, skip that dose and take the next dose at your regular time. Do not make up missed doses.</li>
<li>If you take too many ONMEL, call your local poison control center or go to the nearest hospital emergency room right away.</li>
</ul>
<p><span class="Bold">What are the possible side effects of ONMEL?</span></p>
<p><span class="Bold">ONMEL can cause serious side effects, including:</span></p>
<ul class="Disc">
<li><span class="Bold">See "<a href="#important">What is the most important information I should know about ONMEL?</a>"</span></li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span></span>. <span class="Bold">Stop taking ONMEL and call your doctor right away if you have symptoms of <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span> including:</span><table class="Noautorules" width="75%">
<col align="left" valign="top" width="50%">
<col align="left" valign="top" width="50%">
<tbody class="Headless"><tr>
<td align="left"><ul class="Disc">
<li>unusually tired</li>
<li>lose your appetite</li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></li>
<li><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span></li>
</ul></td>
<td align="left"><ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></li>
<li>yellow change in the color of   your skin or eyes</li>
<li>dark colored urine</li>
<li><span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> stools (bowel movements)</li>
</ul></td>
</tr></tbody>
</table>
</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="381732" conceptname="Nerve injury">nerve damage</span> </span>(<span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span>). Call your doctor right away if you have <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span> or <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span> in your hands or feet. You may need to stop taking ONMEL if this happens.</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hearing loss</span>. </span><span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">Hearing loss</span> can happen for a short time or permanently in some people who take ONMEL with other medications. Stop taking ONMEL and call your doctor right away if you have any changes in your hearing.</li>
</ul>
<p><span class="Bold">Common side effects of ONMEL include:</span></p>
<table class="Noautorules" width="75%">
<col align="left" valign="top" width="60%">
<col align="left" valign="top" width="40%">
<tbody class="Headless"><tr>
<td align="left"><ul class="Disc">
<li>increased liver enzyme in blood test results</li>
<li><span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory infection</span> or <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> (<span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">runny nose</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> and sneeze)</li>
<li><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span> (burning and <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">painful urination</span>)</li>
<li><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span></li>
<li><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></li>
</ul></td>
<td align="left"><ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></li>
<li><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span></li>
<li><span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">throat pain</span></li>
<li><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span></li>
</ul></td>
</tr></tbody>
</table>
<p>These are not all of the possible side effects of ONMEL. Tell your doctor if you any side effect that bothers you or that does not go away. For more information, ask your doctor.</p>
<p><span class="Bold">Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</span></p>
<p><span class="Bold">How should I store ONMEL?</span></p>
<ul class="Disc">
<li>Store at controlled room temperature between 59° to 77°F (15° to 25°C).</li>
<li>Keep ONMEL away from light and moisture.</li>
<li>Keep ONMEL and all medicines out of reach of children.</li>
</ul>
<p><span class="Bold">General Information:</span></p>
<p>Medicines are sometimes prescribed for conditions that are not mentioned in Patient Information leaflets. Do not use ONMEL for a condition for which it was not prescribed. Do not give ONMEL to other people, even if they have the same symptoms that you have. It may harm them.</p>
<p>This leaflet summarizes the most important information about ONMEL. If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information about ONMEL that is written for health professionals.</p>
<p>For more information about ONMEL call 1-877-743-8454.</p>
<p><span class="Bold">What are the ingredients in ONMEL?</span></p>
<p>Active ingredient:  itraconazole</p>
<p>Inactive ingredients: colloidal silicon dioxide, crospovidone, hydrogenated vegetable oil, hypromellose, lactose, magnesium stearate, microcrystalline cellulose, propylene glycol, talc, and titanium dioxide.</p>
<p>The following are registered trademarks of their respective manufacturers:</p>
<p>Dolophine<span class="Sup">®</span> (Roxane Laboratories, Inc), Mevacor<span class="Sup">®</span> (Merck &amp; Co., Inc.), Advicor<span class="Sup">®</span> (Kos Pharmaceuticals, Inc.), Altocor™ (Andrx Laboratories), Zocor<span class="Sup">®</span> (Merck &amp; Co., Inc.), Halcion<span class="Sup">®</span> (Pharmacia), Versed<span class="Sup">®</span> (Roche Pharmaceuticals), Cardioquin<span class="Sup">®</span> (The Purdue Frederick Company), Quinaglute<span class="Sup">®</span> (Berlex Laboratories), Quinidex<span class="Sup">®</span> (A.H. Robins), Tikosyn™ (Pfizer, Inc.), Propulsid<span class="Sup">®</span> (Janssen Pharmaceutica Products, L.P.), Orlaam<span class="Sup">®</span> (Roxane Laboratories), Migranal<span class="Sup">®</span> (Xcel Pharmaceuticals), Ergonovine (PDRX Pharmaceuticals), Cafergot<span class="Sup">®</span> (Novartis Pharmaceuticals Corporation), Methergine<span class="Sup">®</span> (Novartis Pharmaceuticals Corporation), Orap<span class="Sup">®</span> (Gate Pharmaceuticals), and Sular<span class="Sup">®</span> (First Horizon Pharmaceutical Corporation)</p>
<p><span class="Bold">What happens if I have a fungal <span class="product-label-link" type="condition" conceptid="4080305" conceptname="Infection of nail">nail infection</span>?</span></p>
<p>Anyone can have a fungal <span class="product-label-link" type="condition" conceptid="4080305" conceptname="Infection of nail">nail infection</span>, but it is usually found in adults. When a fungus infects the nail, the infected part of the nail may turn yellow or brown. If not treated, the fungus may spread, and more of the nail may change color, may become thick or brittle, and the tip of the nail may become raised. In some patients, this can cause <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span>.</p>
<p>Manufactured by:<br>Sanico N.V.<br>2300 Turnhout, Belgium</p>
<p>Manufactured for<br>Merz Pharmaceuticals, LLC<br>4215 Tudor Lane<br>Greensboro, NC 27410</p>
<p>5011889</p>
<p>10/2012</p>
<p>ONM:3PIL</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-18"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 28 Tablet Carton</span></p>
<p>NDC 0259-1420-28</p>
<p><span class="Bold">Rx Only</span></p>
<p>MERZ</p>
<p>2 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Cards<br>28 Tablets Total<br>Each <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> card contains<br>14 Tablets</p>
<p><span class="Bold">ONMEL</span>™<br><span class="Bold">(itraconazole) Tablets 200 mg</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 28 Tablet Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=fb8a2e5b-fd23-4977-81de-a95f4af168e2&amp;name=onmel-02.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ONMEL 		
					</strong><br><span class="contentTableReg">itraconazole tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0259-1420</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ITRACONAZOLE</strong> (ITRACONAZOLE) </td>
<td class="formItem">ITRACONAZOLE</td>
<td class="formItem">200 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Silicon Dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Crospovidone</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Hypromelloses</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Lactose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Cellulose, Microcrystalline</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Magnesium Stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Propylene Glycol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Talc</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Titanium Dioxide</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (white to slightly grey) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">FREEFORM (oblong) </td>
<td class="formLabel">Size</td>
<td class="formItem">19mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">BARRIER;IT200</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0259-1420-28</td>
<td class="formItem">2  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0259-1420-14</td>
<td class="formItem">14  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022484</td>
<td class="formItem">11/01/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Merz Pharmaceuticals, LLC
							(126209282)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Sanico N.V.</td>
<td class="formItem"></td>
<td class="formItem">282896711</td>
<td class="formItem">MANUFACTURE(0259-1420)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 11/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>03eb05c6-af6e-453e-828e-247d91eb6185</div>
<div>Set id: fb8a2e5b-fd23-4977-81de-a95f4af168e2</div>
<div>Version: 1</div>
<div>Effective Time: 20121105</div>
</div>
</div> <div class="DistributorName">Merz Pharmaceuticals, LLC</div></p>
</body></html>
